NeuroPace Prepares for AAN 2025 Annual Meeting
MOUNTAIN VIEW, Calif. — NeuroPace, Inc. (NASDAQ: NPCE), a pioneering medical device company, is gearing up for an impactful presence at the upcoming American Academy of Neurology (AAN) Annual Meeting in San Diego. From April 5 to 9, the company will shed light on significant data derived from their Post-Approval Study (PAS) focusing on the RNS System, which is tailored for adults battling drug-resistant focal epilepsy (DRE).
Transforming Lives with Innovative Solutions
Living with drug-resistant focal epilepsy is often challenging, with many patients experiencing lifelong seizure difficulties that are unresponsive to traditional drug therapies. Joel Becker, the CEO of NeuroPace, emphasized the urgency to address this unmet need, stating, “We are dedicated to supporting individuals affected by drug-resistant focal epilepsy and are eager to present data that can potentially transform their lives at the AAN 2025.”
Inside the RNS System
The RNS System by NeuroPace stands out as the first and only brain-responsive platform that provides real-time, personalized seizure treatment, marking a significant advancement in patient care. Attendees at the AAN Annual Meeting can witness the RNS System firsthand at booth #1642, which will provide an in-depth look at this cutting-edge technology.
Highlights of NeuroPace Presentations
NeuroPace is set to engage with the neurological community through various presentations at the AAN Annual Meeting:
- Oral Presentation: Multicenter Post-Approval Study of the RNS System in Focal Epilepsy
Monday, April 7, from 5:06 PM to 5:18 PM PDT in SDCC Room 29A.
This presentation will be conducted by Dawn Eliashiv, MD, FAAN, from UCLA. - Presentation of the PAS Study at the Exhibitor Hall Stage
Tuesday, April 8, from 12:00 PM to 12:20 PM PDT at the Exhibitor Presentation Stage Aisle 2100.
Martha Morrell, MD, Chief Medical Officer, and Barbara Jobst, MD from Dartmouth will lead this session. - Encore Presentations: Multicenter Post-Approval Study of the RNS System in Focal Epilepsy
Clinicians unable to attend can participate through an encore webinar on Tuesday, April 8, at 8:00 AM PDT and Friday, April 11, at 12:00 PM PDT, with presentations from Martha Morrell, MD and Dawn Eliashiv, MD.
Looking to the Future: NeuroPace's Vision
NeuroPace remains committed to advancing its RNS System as a key treatment option for drug-resistant epilepsy, emphasizing the platform's potential to improve the quality of life for countless patients. The company is poised to lead the way in establishing better care standards and personalized solutions for individuals grappling with severe brain disorders.
More Information
Attendees interested in learning more about the RNS System are invited to visit NeuroPace at booth #1642 during the AAN Annual Meeting. For those unable to attend, comprehensive information can be explored at their official website.
Frequently Asked Questions
What is NeuroPace, Inc.?
NeuroPace, Inc. is a medical device company dedicated to improving the lives of those with epilepsy through innovative technology, notably the RNS System.
What is the RNS System?
The RNS System is a unique neuromodulation platform designed to deliver personalized, real-time treatment for patients with drug-resistant focal epilepsy.
Where will NeuroPace present their study data?
NeuroPace will present its study data during the AAN 2025 Annual Meeting in San Diego, with specific sessions on April 7 and April 8.
How can I attend the encore presentations?
Clinicians can join the encore presentations that will be held online on April 8 and April 11; registration details will be available through NeuroPace.
How does the RNS System benefit patients?
The RNS System aims to provide patients with real-time treatment options, addressing seizures more effectively than traditional medications.
